It was proved that metformin can directly affect primary breast cancer in vivo, including the downregulation of phosphodiesterase 3B (PDE3B), a critical regulator of cAMP synthesis, which combined with AMPK activation, can be considered as adjuvant breast cancer therapy [163]. The gene discussed is PDE3B; the disease is breast cancer.